Author： D'Anneo Antonella Rood Pleunie Bottino Rita Balamurugan A. He Jing Giannoukakis Nick
Publisher： Humana Press, Inc
ISSN： 0257-277X
Source： Immunologic Research, Vol.36, Iss.1-3, 2006-02, pp. : 83-89
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
This review, in addition to updating the growing list of type 1 diabetes-relevant gene therapies, offers an outline of short-term objectives that can readily be met to move, at least, adenoviral and adeno-associated viral-based protocols into the clinic, first as a means of facilitating islet allografts as well as platforms with which to introduce immunoregulatory transgenes. A wide array of genes have been tested to restore insulin production, to drive the differentiation of insulin-producing progenitors, and to confer immunosuppression in an antigen-and tissue-restricted manner.
Related content
Recent advances in insulin gene therapy for type 1 diabetes
Trends in Molecular Medicine, Vol. 8, Iss. 2, 2002-02 ,pp. :
Access to resources
Recommend
Gene Therapy for Diabetes Mellitus
Current Molecular Medicine, Vol. 1, Iss. 3, 2001-07 ,pp. :
The potential role of dendritic cells in the therapy of Type 1 diabetes
By Lee Chin-Nien Lew Andrew M Wu Li
Immunotherapy, Vol. 5, Iss. 6, 2013-06 ,pp. :
IPF-1 Gene Variation and the Development of Type 2 Diabetes
Molecular Genetics and Metabolism, Vol. 75, Iss. 3, 2002-03 ,pp. :